VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
157.24
+0.90 (+0.58%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close156.34
Open156.61
Bid145.00 x 900
Ask159.24 x 1100
Day's Range155.33 - 157.52
52 Week Range115.10 - 178.15
Volume829,549
Avg. Volume1,534,811
Market Cap40.069B
Beta1.94
PE Ratio (TTM)151.34
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • MARKETS: Here's why stellar earnings aren't boosting stocks higher
    Yahoo Finance Video13 days ago

    MARKETS: Here's why stellar earnings aren't boosting stocks higher

    Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.

  • MARKETS: Oil markets react to Iran latest, Apple stocks up ahead of earnings report, Walmart helps retails sector
    Yahoo Finance Video20 days ago

    MARKETS: Oil markets react to Iran latest, Apple stocks up ahead of earnings report, Walmart helps retails sector

    Latest market news with Yahoo Finance's Seana Smith and Jared Blikre.

  • Why Wall Street Analysts Are Mostly Positive on CRISPR
    Market Realist2 days ago

    Why Wall Street Analysts Are Mostly Positive on CRISPR

    In December 2017, CRISPR Therapeutics (CRSP) entered a collaboration with Vertex Pharmaceuticals (VRTX) for the co-development and co-commercialization of CTX001. CRISPR Therapeutics submitted a CTA (clinical trial application) for CTX001 for the initiation of phase 1/2 trial for the evaluation of the safety and efficacy in the treatment of beta-thalassemia in Europe. CRISPR Therapeutics plans to submit an Investigational New Drug application to the FDA for the approval of an initiation of phase 1/2 clinical trial in the US for the treatment of sickle cell disease in the second half of 2018.

  • The Zacks Analyst Blog Highlights: General Dynamics, Enbridge, CSX, Humana and Vertex
    Zacks4 days ago

    The Zacks Analyst Blog Highlights: General Dynamics, Enbridge, CSX, Humana and Vertex

    The Zacks Analyst Blog Highlights: General Dynamics, Enbridge, CSX, Humana and Vertex

  • Investopedia4 days ago

    CRISPR Stocks Deserve a Second Look. Here's Why.

    Clustered Regularly Interspaced Short Palindromic Repeats, commonly known as CRISPR, the revolutionary gene editing method was first discovered by Francisco Monica in Spain, as a means to defend one’s body from invading viruses. To start with, let’s first focus on what exactly the gene editing process entails. Gene editing is primarily inserting, deleting or replacing DNA base pairs within a gene.

  • How Did Jazz Pharmaceuticals Perform in 1Q18?
    Market Realist10 days ago

    How Did Jazz Pharmaceuticals Perform in 1Q18?

    In 1Q18, Jazz Pharmaceuticals (JAZZ) generated revenue of $444.6 million compared to $376.1 million in 1Q17, which reflected an ~18% rise on a YoY (year-over-year) basis and a ~2% rise quarter-over-quarter.

  • See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.
    Markit11 days ago

    See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.

    Vertex Pharmaceuticals Inc NASDAQ/NGS:VRTX

  • 3 Top Biotech Stocks to Buy in May
    Motley Fool11 days ago

    3 Top Biotech Stocks to Buy in May

    Looking for a few timely buys in the biotech space? Give these gems a closer look.

  • 7 Fast-Growing Stocks to Buy Today
    InvestorPlace12 days ago

    7 Fast-Growing Stocks to Buy Today

    Editor’s Note: This is a replay of a story that originally ran March 2, 2018. It has since been updated and republished.

  • Here's My Top Stock to Buy in May
    Motley Fool12 days ago

    Here's My Top Stock to Buy in May

    A near monopoly and multiple paths for growth make this my favorite stock to buy right now.

  • Wall Street Recommendations for Exelixis in May 2018
    Market Realist13 days ago

    Wall Street Recommendations for Exelixis in May 2018

    As per the terms of the agreement, Exelixis and Invenra will jointly discover and develop antibodies with the help of Invenra’s B-Body technology platform, which allows high-throughput screening along with in vitro and in vivo preclinical characterization for the development of potential therapeutic candidates. According to the terms of the agreement, Exelixis will lead preclinical trials, manufacturing, the clinical development of both single-regimen and combination-regimen therapies along with regulatory filling and commercialization. Also under this collaboration, Exelixis and Invenra plan to conduct up to six discovery projects.

  • How Did Exelixis Perform in 1Q18?
    Market Realist16 days ago

    How Did Exelixis Perform in 1Q18?

    In 1Q18, Exelixis (EXEL) generated revenues of $212.3 million yesterday, compared to $80.89 million in 1Q17. In 1Q18, Exelixis witnessed ~77% growth on a quarter-over-quarter basis.

  • Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1
    Zacks18 days ago

    Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1

    The biotech sector was in focus over the last five trading sessions as several bigwigs like Gilead and Vertex, among others reported results while some others provided pipeline updates.

  • Medicaid Is Right to Demand Lower Drug Prices
    Bloomberg19 days ago

    Medicaid Is Right to Demand Lower Drug Prices

    Last week, as President Donald Trump delayed announcing his plan to bring down high drug prices, about a dozen physicians, pharmacists, actuaries and economists in Albany, New York, tried to make a difference. The state Medicaid program's Drug Utilization Review Board voted 10-0 to lower the price New York would pay for Orkambi, Vertex Pharmaceuticals' cystic fibrosis drug, to $83,000 per year, from $250,000. As a lung physician, I appreciate that Orkambi does have benefits — it eases breathing and prevents some of the acute episodes that can land cystic fibrosis patients in the hospital.

  • Vertex Pharmaceuticals Takes a Detour Around the FDA's Roadblock
    Motley Fool20 days ago

    Vertex Pharmaceuticals Takes a Detour Around the FDA's Roadblock

    The news shouldn't distract from a solid first quarter.

  • Investopedia20 days ago

    Google's Alphabet Median Pay Close To $200K

    Alphabet Inc. ( GOOG), Google's parent company, paid its employees nearly $200,000 last year, placing it in fourth place in terms of median compensation among S&P 500 Index companies that disclose pay. Citing Alphabet, the Wall Street Journal reported that in 2017 it had median pay packages of more than $197,000, which was 18% below Facebook Inc. ( FB) where the median salary was $240,000 in 2017. Excluding the two, which are embroiled in a talent war with other technology companies, the median salary for companies in the S&P 500 was $69,205, noted the Wall Street Journal.

  • Thomson Reuters StreetEvents20 days ago

    Edited Transcript of VRTX earnings conference call or presentation 26-Apr-18 8:30pm GMT

    Q1 2018 Vertex Pharmaceuticals Inc Earnings Call

  • Forbes21 days ago

    Stocks This Week: Buy Visa, Vertex And Apple

    This is the period of end-of-the-month strength in the stock market. In addition, the bullish odds are increased by the Federal Open Market Committee meeting in the coming week on May 1-2. Vertex Pharmaceuticals yields a cycle buy signal on May 1.

  • 5 Things You'll Want to Know From Vertex Pharmaceuticals' Q1 Conference Call
    Motley Fool21 days ago

    5 Things You'll Want to Know From Vertex Pharmaceuticals' Q1 Conference Call

    What the biotech's management had to say about what's next for Vertex.

  • Analysts’ Recommendations for Vertex Pharmaceuticals
    Market Realist23 days ago

    Analysts’ Recommendations for Vertex Pharmaceuticals

    In February 2018, Vertex Pharmaceuticals (VRTX) announced the results of a Phase 2 trial for VX-150, an investigational NaV1.8 inhibitor. It had positive results in patients with acute pain after bunion removal and was well tolerated by patients.

  • Vertex Slips As FDA Delays Cystic Fibrosis Drug — But There's A Silver Lining
    Investor's Business Daily23 days ago

    Vertex Slips As FDA Delays Cystic Fibrosis Drug — But There's A Silver Lining

    Vertex slid to a three-week low Friday after the FDA required additional tests for one compound used in a potential cystic fibrosis regimen.

  • How Did Vertex Pharmaceuticals Perform in 1Q18?
    Market Realist23 days ago

    How Did Vertex Pharmaceuticals Perform in 1Q18?

    In 1Q18, Vertex Pharmaceuticals’ (VRTX) revenue rose ~33% YoY (year-over-year) to $638 million from $481 million. It grew ~3% quarter-over-quarter.

  • Vertex (VRTX) Q1 Earnings Beat on Strong CF Products Sales
    Zacks23 days ago

    Vertex (VRTX) Q1 Earnings Beat on Strong CF Products Sales

    Vertex Pharma (VRTX) first-quarter earnings increase from the year-ago period led by strong sales trend of CF drugs.

  • Reuters24 days ago

    Vertex Pharma profit tops estimates on strong launch of new CF drug

    Vertex Pharmaceuticals Inc topped analysts' forecasts for quarterly profit on Thursday, led by stronger-than expected sales of its latest cystic fibrosis drug as well as double-digit growth in sales of older treatments. Boston-based Vertex, like other biotech firms developing drugs for rare diseases, has received enormous interest from investors attracted to the value from pricey treatments for conditions such as cystic fibrosis. Vertex is a leader in treatments for cystic fibrosis (CF), a rare, life-shortening genetic disease that affects some 75,000 people in North America, Europe and Australia, and causes progressive lung damage and loss of lung function.

  • What Analysts Recommend for Neurocrine Biosciences in April 2018
    Market Realist24 days ago

    What Analysts Recommend for Neurocrine Biosciences in April 2018

    In April 2018, the US FDA (Food and Drug Administration) notified Neurocrine Biosciences and AbbVie (ABBV) that it would require more time to review additional information associated with the liver function tests provided by AbbVie in addition to it its NDA (new drug application) for Elagolix. The US FDA granted the new PDUFA (Prescription Drug Fee User Act) action date in 3Q18.